产品简要
公司名称 :
赛信通(上海)生物试剂有限公司
产品类型 :
抗体
产品名称 :
Cleaved PARP (Asp214) Antibody (Human Specific)
目录 :
9541
克隆性 :
多克隆
宿主 :
domestic rabbit
共轭标签 :
未共轭
反应物种 :
人类, 大鼠
应用 :
免疫印迹, 免疫组化, 免疫细胞化学, 流式细胞仪
文章摘录数: 54
出版应用/物种/样本/稀释参考文献
  • 免疫印迹; 人类; 1:1000; 图 2c
Goel S, Bhatia V, Kundu S, Biswas T, Carskadon S, Gupta N, et al. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression. Nat Commun. 2021;12:5325 pubmed 出版商
  • 免疫印迹; 人类; 图 1d
Proctor M, Gonzalez Cruz J, Daignault Mill S, Veitch M, Zeng B, Ehmann A, et al. Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers (Basel). 2021;13: pubmed 出版商
  • 免疫印迹; 人类; 图 1c
Oiwa K, Hosono N, Nishi R, Scotto L, O Connor O, Yamauchi T. Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance. BMC Cancer. 2021;21:879 pubmed 出版商
  • 免疫印迹; 人类; 图 3g, s4d
Yi J, Sias Garcia O, Nasholm N, Hu X, Iniguez A, Hall M, et al. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021;23:624-633 pubmed 出版商
  • 免疫印迹; 人类; 图 5b
Lin C, Tsai M, Chen Y, Liu W, Lin C, Hsu K, et al. Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer In Vitro and In Vivo. Biomol Ther (Seoul). 2021;29:551-561 pubmed 出版商
  • 免疫印迹; 大鼠; 1:1000; 图 4a
Gallo S, Spilinga M, Albano R, Ferrauto G, Di Gregorio E, Casanova E, et al. Activation of the MET receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro. Br J Pharmacol. 2020;177:3107-3122 pubmed 出版商
  • 免疫印迹; 人类; 1:1000; 图 1c, s3b, s3c, s3d
Jung J, Lee H, Cao B, Liao P, Zeng S, Lu H. RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53. Oncogene. 2019;: pubmed 出版商
  • 免疫印迹; 人类
Debruyne D, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, et al. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 2019;572:676-680 pubmed 出版商
  • 免疫印迹; 人类; 1:1000; 图 4a
Tacconi E, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, et al. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med. 2019;11:e9982 pubmed 出版商
  • 免疫印迹; 人类; 图 s8e
Xu D, Li X, Shao F, Lv G, Lv H, Lee J, et al. The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62. Sci Adv. 2019;5:eaav4570 pubmed 出版商
  • 免疫印迹; 人类; 图 2c
Göbel A, Breining D, Rauner M, Hofbauer L, Rachner T. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death Dis. 2019;10:91 pubmed 出版商
  • 免疫印迹; 人类; 图 3b
Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172:578-589.e17 pubmed 出版商
  • 免疫印迹; 人类; 图 4c
Cho M, Lee J, Shin M, Kim H, Choi Y, Rho S, et al. TSC-22 inhibits CSF-1R function and induces apoptosis in cervical cancer. Oncotarget. 2017;8:97990-98003 pubmed 出版商
  • 免疫印迹; 人类; 图 4f
Zhou Y, Huang T, Zhang J, Wong C, Zhang B, Dong Y, et al. TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene. 2017;36:6518-6530 pubmed 出版商
  • 免疫印迹; 人类; 图 s5
Shin C, Lee M, Han J, Jeong S, Ryu B, Chi S. Identification of XAF1-MT2A mutual antagonism as a molecular switch in cell-fate decisions under stressful conditions. Proc Natl Acad Sci U S A. 2017;114:5683-5688 pubmed 出版商
  • 免疫印迹; 人类; 图 s5b
Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, et al. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017;31:685-696.e6 pubmed 出版商
  • 免疫印迹; 人类; 图 6c
Kitazawa S, Ebara S, Ando A, Baba Y, Satomi Y, Soga T, et al. Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. Oncotarget. 2017;8:28922-28938 pubmed 出版商
  • 免疫印迹; 人类; 图 1c
Yang H, Ju F, Guo X, Ma S, Wang L, Cheng B, et al. RNA-binding protein RBM3 prevents NO-induced apoptosis in human neuroblastoma cells by modulating p38 signaling and miR-143. Sci Rep. 2017;7:41738 pubmed 出版商
  • 免疫印迹; 人类; 1:1000; 图 1g
Tagal V, Wei S, Zhang W, Brekken R, Posner B, Peyton M, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098 pubmed 出版商
  • 免疫印迹; 人类; 图 1k
Herold N, Rudd S, Ljungblad L, Sanjiv K, Myrberg I, Paulin C, et al. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 2017;23:256-263 pubmed 出版商
  • 免疫印迹; 人类; 1:1000; 图 4b
Chao T, Zhou X, Cao B, Liao P, Liu H, Chen Y, et al. Pleckstrin homology domain-containing protein PHLDB3 supports cancer growth via a negative feedback loop involving p53. Nat Commun. 2016;7:13755 pubmed 出版商
  • 免疫印迹; 人类; 图 5a
Sha J, Xue W, Dong B, Pan J, Wu X, Li D, et al. PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer. Oncotarget. 2017;8:6114-6129 pubmed 出版商
  • 免疫印迹; 人类; 图 1d
Ishikawa Y, Gamo K, Yabuki M, Takagi S, Toyoshima K, Nakayama K, et al. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells. Mol Cancer Ther. 2017;16:273-284 pubmed 出版商
  • 免疫印迹; 人类; 图 7g
McKenzie C, D Avino P. Investigating cytokinesis failure as a strategy in cancer therapy. Oncotarget. 2016;7:87323-87341 pubmed 出版商
  • 免疫印迹; 人类; 图 2d
Zhao Y, Fan D, Ru B, Cheng K, Hu S, Zhang J, et al. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells. Eur J Cancer. 2016;68:38-50 pubmed 出版商
  • 免疫印迹; 人类; 1:200; 图 st1
Treindl F, Ruprecht B, Beiter Y, Schultz S, Döttinger A, Staebler A, et al. A bead-based western for high-throughput cellular signal transduction analyses. Nat Commun. 2016;7:12852 pubmed 出版商
  • 免疫印迹; 人类; 图 5f
Horn T, Ferretti S, Ebel N, Tam A, Ho S, Harbinski F, et al. High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. Cancer Res. 2016;76:6950-6963 pubmed
  • 免疫印迹; 人类; 图 1a
Zhang Q, Jin R, Zhang X, Sheng J, Yu F, Tan R, et al. The putative oncotarget CSN5 controls a transcription-uncorrelated p53-mediated autophagy implicated in cancer cell survival under curcumin treatment. Oncotarget. 2016;7:69688-69702 pubmed 出版商
  • 免疫印迹; 人类; 1:1000; 图 3d,4b,5e,7b
Grinshtein N, Rioseco C, Marcellus R, UEHLING D, Aman A, Lun X, et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget. 2016;7:59360-59376 pubmed 出版商
  • 免疫印迹; 人类; 图 3c
Ranjan A, Srivastava S. Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis. Sci Rep. 2016;6:26165 pubmed 出版商
  • 免疫印迹; 人类; 图 s2
Chowdhury B, Porter E, Stewart J, Ferreira C, Schipma M, Dykhuizen E. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma. PLoS ONE. 2016;11:e0153718 pubmed 出版商
  • 免疫印迹; 人类; 图 4
Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, et al. Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Cancer Sci. 2016;107:1022-8 pubmed 出版商
  • 免疫印迹; 人类; 图 3
Xiao L, Shi X, Zhang Y, Zhu Y, Zhu L, Tian W, et al. YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells. Onco Targets Ther. 2016;9:1105-14 pubmed 出版商
  • 免疫印迹; 人类; 图 1
Yosef R, Pilpel N, Tokarsky Amiel R, Biran A, Ovadya Y, Cohen S, et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun. 2016;7:11190 pubmed 出版商
  • 免疫印迹; 人类; 1:2000; 图 7
Liu X, Xiao Z, Han L, Zhang J, Lee S, Wang W, et al. LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress. Nat Cell Biol. 2016;18:431-42 pubmed 出版商
  • 免疫印迹; 人类; 图 3d
Lee J, Kim H, Rho S, Lee S. eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells. Oncotarget. 2016;7:18541-57 pubmed 出版商
  • 免疫印迹; 人类; 图 3
Du Z, Li L, Huang X, Jin J, Huang S, Zhang Q, et al. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget. 2016;7:21618-30 pubmed 出版商
  • 免疫印迹; 人类; 1:1000; 图 s3
Zhang W, Shi H, Zhang M, Liu B, Mao S, Li L, et al. Poly C binding protein 1 represses autophagy through downregulation of LC3B to promote tumor cell apoptosis in starvation. Int J Biochem Cell Biol. 2016;73:127-136 pubmed 出版商
  • 免疫印迹; 人类; 图 1
Luey B, May F. Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer. 2016;15:8 pubmed 出版商
  • 免疫印迹; 人类; 图 6a
Moriwaki K, Chan F. Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome. J Biol Chem. 2016;291:5948-59 pubmed 出版商
  • 免疫印迹; 人类; 图 2f
van Geldermalsen M, Wang Q, Nagarajah R, Marshall A, Thoeng A, Gao D, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35:3201-8 pubmed 出版商
Blakely C, Watkins T, Wu W, Gini B, Chabon J, McCoach C, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49:1693-1704 pubmed 出版商
Zhou Y, Huang T, Siu H, Wong C, Dong Y, Wu F, et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol Cancer. 2017;16:77 pubmed 出版商
Nunes J, Pandey S, Yadav A, Goel S, Ateeq B. Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. Neoplasia. 2017;19:333-345 pubmed 出版商
Mason J, Wei X, Fletcher G, Kiarash R, Brokx R, Hodgson R, et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017;114:3127-3132 pubmed 出版商
Connelly K, Martin E, Dykhuizen E. CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme. Yale J Biol Med. 2016;89:431-440 pubmed
Exell J, Thompson M, Finger L, Shaw S, Debreczeni J, Ward T, et al. Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site. Nat Chem Biol. 2016;12:815-21 pubmed 出版商
Kim J, Jung Y, Choi B, Lee N, Lee H, Kwak S, et al. Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules. Oncotarget. 2016;7:53178-53190 pubmed 出版商
Saisana M, Griffin S, May F. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget. 2016;7:54445-54462 pubmed 出版商
Kuo H, Kakadiya R, Wu Y, Su T, Lee T, Lin Y, et al. Derivatives of 6-cinnamamido-quinoline-4-carboxamide impair lysosome function and induce apoptosis. Oncotarget. 2016;7:38078-38090 pubmed 出版商
Huang T, Kang W, Zhang B, Wu F, Dong Y, Tong J, et al. miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-κB signaling in gastric carcinogenesis. Mol Cancer. 2016;15:9 pubmed 出版商
Trošt N, Peña Llopis S, Koirala S, Stojan J, Potts P, Fon Tacer K, et al. γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers. Oncotarget. 2016;7:2611-28 pubmed 出版商
Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016;22:1138-49 pubmed 出版商
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. 2016;35:1541-53 pubmed 出版商
产品信息
SKU号 :
9541S
产品名称 :
Cleaved PARP (Asp214) Antibody (Human Specific)
规格 :
100微升
Price-(USD) :
274美元
物种x :
H
应用 :
免疫印迹
产品种类 :
凋亡
运输温度 :
AMBIENT
储存温度 :
-20°C
产品类型 :
多克隆抗体
分子量 :
89
宿主 :
靶标 :
PARP1 (Asp214, 89 kD) cleaved
最初蛋白 :
多聚(ADP-核糖)聚合酶
别名 :
ADP-ribosyltransferase (NAD+,ADP-ribosyltransferase NAD(+),ADPRT,ADPRT 1,ADPRT1,NAD(+) ADP-ribosyltransferase 1,PARP,PARP-1,PARP1,PPOL,Poly [ADP-ribose] polymerase 1,Poly[ADP-ribose] synthase 1,pADPRT-1,poly (ADP-ribose) polymerase 1,poly (ADP-ribose) polymerase family, member 1,poly (ADP-ribose) polymerase),poly(ADP-ribose) polymerase,poly(ADP-ribose) synthetase,poly(ADP-ribosyl)transferase
公司信息
赛信通(上海)生物试剂有限公司
上海市浦东南路1101号远东大厦514室,200120
info@cst-c.com.cn
http://www.cst-c.com.cn
2158356288
公司总部: 美国
赛信通生物试剂有限公司1999年成立于美国麻省,是一家私人拥有的公司,在全世界拥有超过400名员工。我们致力于提供用于帮助确定的细胞功能和抗病机制的创新型的研究工具。公司自成立以来,赛信通已成为全球领先的生产用于扩大细胞信号通路知识的最高质量的激活状态蛋白和总蛋白的抗体。我们的使命是为客户提供世界上最高质量的研究工具,以加快生物研究和个性化药物的进展。